No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

After a 20% stock plunge, Denmark's prized drugmaker triggers fears over jobs, confidence, and consumer spending.

Shares in Novo Nordisk, which makes Wegovy and Ozempic, are down 45pc so far this year as it battles competition from rival ...

Demand for Novo Nordisk A/S’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: ...

Hyderabad-based Natco Pharma, through its legal representative, reportedly stated that it had reached out to the Danish drugmaker multiple times in recent months to discuss its non-infringing patents ...